Showing 661-670 of 9358 results for "".
- HydraFacial and Vesper Healthcare Announce Closing of Business Combination, Combined Company Now Known as The Beauty Health Companyhttps://practicaldermatology.com/news/hydrafacial-and-vesper-healthcare-announce-close-business-combination-combined-company-now-known-as-the-beauty-health-company/2460800/It's officially official: Vesper Healthcare and The HydraFacial Company closed their previously announced business combination. The combined company will be known as The Beauty Health Company. The business combination was approved by Vesper Healthcare’s stockholders on April 29, 2021, with approx…
- Arcutis to Present New Data for Roflumilast in PsO at EADVhttps://practicaldermatology.com/news/arcutis-to-present-new-data-for-roflumilast-in-pso-at-eadv/2460798/New data from the DERMIS-1 and DERMIS-2 pivotal phase 3 studies evaluating roflumilast cream (ARQ-151) show that the investigational once daily, topical PDE4 inhibitor for psoriasis achieved the primary efficacy endpoint of IGA success at week eight for chronic plaque psoriasis. Data are being pres…
- UCB’s Bimekizumab Outplays the Competition in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ucbs-bimekizumab-outplays-the-competition-in-two-phase-3-psoriasis-trials/2460764/UCB’s Bimekizumab almost entirely cleared moderate to severe psoriasis in more than 60 percent of the patients who took part in two Phase 3 clinical trials. Given via injection under the skin, Bimekizumab is a monoclonal antibody and the first to block both Interleukin 17A and Interleukin 17F whic…
- Journey Medical to Acquire Dermira's Qbrexzahttps://practicaldermatology.com/news/journey-medical-to-acquire-dermiras-qbrexza/2460731/Journey Medical Corporation, a partner company of Fortress Biotech, Inc., has entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the US from Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company. The transaction is expected to close early in the second quarter o…
- FDA Approves Galderma's Restylane Defyne for Chin Augmentationhttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-defyne-for-chin-augmentation/2460676/The U.S. Food and Drug Administration (FDA) has approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion in adults over the age of 21. Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 2016 by the FDA for mid-to-deep injecti…
- Ortho Dermatologics Launches Telemedicine on Dermatology.com, US Cash-Pay Prescription Programhttps://practicaldermatology.com/news/ortho-dermatologics-launches-telemedicine-on-dermatologycom-us-cash-pay-prescription-program/2460285/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, launched a new telemedicine platform on Dermatology.com, the first and only non-reimbursed, cash-pay prescription program in dermatology in the United States. The enhanced website will offer patients the ability to cons…
- Acne Pipeline Watch: Dermata Therapeutics Completes Enrollment in Phase 2b Trial of Once-Weekly Topical DMT310 for Acnehttps://practicaldermatology.com/news/acne-pipeline-watch-dermata-therapeutics-completes-enrollment-in-phase-2b-trial-of-once-weekly-topical-dmt310-for-acne/2460282/Dermata Therapeutics, LLC completed enrollment of patients in its Phase 2b clinical trial evaluating the safety, tolerability and efficacy of DMT310 in moderate to severe acne patients. The Phase 2b trial enrolled 182 patients randomly in two groups, DMT310 or placebo, at 14 sites across the Unite…
- Electric Tech May Help Reverse Baldnesshttps://practicaldermatology.com/news/electric-tech-may-help-reverse-baldness/2460156/Reversing baldness could someday be as easy as wearing a hat, thanks to a noninvasive, low-cost hair-growth-stimulating technology developed by engineers at the University of Wisconsin–Madison. Xudong Wang, a professor of materials science and engineering at UW–Madison. and colleagues published a …
- Ortho Dermatologics Expands Cash-Pay Prescription Program with Walgreens Agreementhttps://practicaldermatology.com/news/ortho-dermatologics-expands-cash-pay-prescription-program-with-walgreens-agreement/2460115/Ortho Dermatologics’ Cash-Pay Prescription Plan is now available at Walgreen’s stores nationwide. Under the expanded agreement, Walgreens patients will have access to the select dermatology products included in Ortho Dermatologics’ first-of-its-kind cash-pay prescription program, Dermatology.com,…
- Candela Unveils New Corporate Identity at the 2019 AAD Annual Meetinghttps://practicaldermatology.com/news/candela-unveils-new-corporate-identity-at-the-2019-aad-annual-meeting/2459874/Syneron-Candela has rebranded the company to Candela and unveiled its new corporate branding at the American Academy of Dermatology (AAD) Annual Meeting. The new corporate identity reflects the unification of the Syneron and Candela brands and is designed to support continued global market growth a…